⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Supplementary Figure 12 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors

View Full Paper

Ask AI

Bookmark

Share

Abstract

AMT-562 is more effective as single agent or in combination therapy for colorectal cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Weng et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db64358752376a https://doi.org/10.1158/1535-7163.27036196

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 12 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
2Supplementary Figure 5 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
3Supplementary Figure 5 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
4Supplementary Figure 11 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
5Supplementary Figure 11 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024